Login to Your Account

Following BMS And Abbott

Lilly Taps Iconix's Platform Of 'Drug Signature' Research

By Randall Osborne

Friday, November 18, 2005
Iconix Pharmaceuticals Inc.'s chemogenomics platform bagged another big-name pharma deal, this time signing up Eli Lilly and Co. to a research and license agreement described as "similar in scope" to last year's pacts with Bristol-Myers Squibb Co. and Abbott Laboratories Inc. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription